Rhumbline Advisers Has $4.41 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Rhumbline Advisers reduced its holdings in Arrowhead Pharmaceuticals by 9.0%, owning approximately 0.25% of the company after selling 34,365 shares.
• Multiple institutional investors have increased their positions, with notable growth by Focus Partners Wealth at 1,339.5% and Goldman Sachs Group Inc. at 34.6%.
• Arrowhead Pharmaceuticals reported a larger-than-expected EPS loss of ($1.26) for the last quarter, missing analyst estimates of ($0.94), alongside a revenue of $27.77 million.

Rhumbline Advisers trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 9.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 345,979 shares of the biotechnology company's stock after selling 34,365 shares during the quarter. Rhumbline Advisers owned approximately 0.25% of Arrowhead Pharmaceuticals worth $4,408,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ARWR. Vanguard Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock worth $168,201,000 after buying an additional 1,018,273 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock worth $60,962,000 after buying an additional 2,774,933 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Arrowhead Pharmaceuticals by 0.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company's stock worth $32,220,000 after buying an additional 21,686 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after buying an additional 447,456 shares during the last quarter. Finally, Aberdeen Group plc boosted its holdings in Arrowhead Pharmaceuticals by 138.4% during the first quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company's stock worth $13,668,000 after buying an additional 622,752 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the completion of the transaction, the insider owned 232,122 shares in the company, valued at $6,963,660. This trade represents a 6.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 40,000 shares of company stock valued at $1,025,000 over the last three months. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ARWR shares. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Royal Bank Of Canada cut their price objective on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. B. Riley raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Finally, Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR traded down $0.82 during trading on Friday, reaching $30.69. 4,937,943 shares of the company traded hands, compared to its average volume of 2,707,305. The company's 50 day moving average is $21.17 and its two-hundred day moving average is $16.95. The firm has a market capitalization of $4.24 billion, a PE ratio of -23.98 and a beta of 1.00. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $31.67.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same period in the prior year, the company posted ($1.38) EPS. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.